Duration disease free survival. Medical search. Frequent questions

Patients received melphalan flufenamide 40 mg intravenously on day 1 and dexamethasone 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, 15 and 22 of each 28-day cycle until disease progression or unacceptable toxicity. (wikipedia.org)
For patients with MCL, CLL, or SLL, the recommended dose of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. (drugs.com)
Patients received a dose every 3 weeks until disease progression or unacceptable toxicity. (cancernetwork.com)
The recommended dosage of VIZIMPRO is 45 mg taken orally once daily, until disease progression or unacceptable toxicity occurs. (nih.gov)

The primary endpoint was median progression-free survival. (nih.gov)
Progression-free survival was the primary endpoint, whereas overall response rate, duration of response, disease control rate, clinical benefit rate, and overall survival were secondary outcomes. (news-medical.net)
Invasive disease-free survival was the primary endpoint of the study. (nepalnews.com)
The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
The primary endpoint for the papillary cohort was the disease-free survival (DFS) rate at 12 months. (renalandurologynews.com)
The primary endpoint of ELM-2 is objective response rate according to the Lugano Classification, and secondary endpoints include complete response, progression-free survival, overall survival, duration of response, disease control rate, safety and quality of life. (biospace.com)

The invasive disease-free survival rates at three years were 90.4%, compared to 87.1% for women who were treated with only hormone therapy. (nepalnews.com)
Looking specifically at people in the study who had Ki-67 scores of 20 percent or higher, the researchers found an even larger difference in 2 year invasive disease-free survival rates. (lbbc.org)

Median duration of response (mDOR) and progression-free survival (mPFS) was not reached. (biospace.com)
When patients whose tumors bear the sensitizing mutations are treated with the tyrosine kinase inhibitors gefitinib or erlotinib, we witness response rates and durations never before reported, including complete responses. (aacrjournals.org)
In a Phase 1/2 trial, in solid tumor patients refractory to standard therapy, response evaluation showed disease stabilization in a majority of patients. (wikipedia.org)
the median Progression-Free Survival was 9.4 months and the Duration of Response was 9.6 months. (wikipedia.org)
Median response duration for responders was 20.2 months, with only seven having disease progression as of May 2013. (sciencedaily.com)
The research team examined blood samples and tumor biopsies to identify possible risk factors and genes that might indicate response to treatment and survival. (sciencedaily.com)
Gene expression analysis of tumor samples from 18 patients before treatment showed that progression-free survival increased for patients when their gene signature included genes that are highly active during T cell response or repressed in regulatory T cells that dampen T cell activation," said Eric Davis, M.D., associate professor of Lymphoma/Myeloma and co-senior author of the paper. (sciencedaily.com)
The continued durable response and significant improvement in survival indicated by these new data can potentially establish a new standard of care for adult patients living with this aggressive form of leukemia. (gilead.com)
The journal concluded that orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in patients with relapsed or refractory MZL. (businesswire.com)
The IRC-assessed median duration of response (DOR) was 34.3 months and median progression-free survival (PFS) was not reached. (businesswire.com)
High response rates were consistent among patients with different MZL subtypes and those with negative disease prognostic factors at baseline. (businesswire.com)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
Furthermore, the difference in objective response rates and the proportion of patients with disease stabilization between panitumumab and best supportive care alone demonstrated the significant activity of this agent. (amgen.com)
Study investigators also reported that panitumumab significantly improved disease control versus BSC alone (36 percent versus 10 percent, respectively), as measured by response rate and stable disease. (amgen.com)
The objective, independently evaluated response rate was eight percent with panitumumab versus zero with BSC alone, and the median duration of response was 17 weeks. (amgen.com)
In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
Panitumumab improved progression-free survival and response rate regardless of the measured level or intensity of EGFr staining. (amgen.com)
In both cases-incomplete response or complete remission—if the disease eventually relapses, clinicians will move to salvage therapy. (pharmacytimes.com)
Median duration of response was not reached. (ascopost.com)
To date, progression free survival (PFS) and duration of response (DOR) have not been reached. (itbusinessnet.com)
TECENTRIQ is approved under accelerated approval for this indication based on tumor response rate and duration of response. (przoom.com)
Patients treated with the combination treatment had high rates of complete response (CR), cystectomy avoidance, and cancer-specific survival. (renalandurologynews.com)
Such dynamic effect has long been clinically underestimated, as the tumor initial response has been more of a focus than its duration of response. (scirp.org)
That said, Her 2 positive breast cancer response to Herceptin, (if there is no inherent or acquired resistance reported) has a quantity and duration with a range of negligible to significant and between few weeks to years, depending of the clinical study performed and the candidates specific tumor character included in the studied. (scirp.org)
Surgery may be indicated in patients who have locally advanced or previously unresectable disease after a positive response to preoperative imatinib, in addition to limited disease progression on systemic therapy. (medscape.com)
The study uses innovative statistical methods - parametric survival models with change points - to study the incidence of new onset obstructive airway disease (OAD) diagnoses and symptoms over the first ten years following WTC exposure, with the goal of determining the length of time that exposure response gradients are observed among exposed FDNY firefighters. (cdc.gov)
What is the magnitude of the exposure-response relationship between WTC exposure and incident obstructive airway disease? (cdc.gov)
The duration of an exposure response gradient between incident obstructive airways disease and work at the World Trade Center site: 2001-2011. (cdc.gov)

Newer studies with intensive multiagent chemotherapy (eg, the CALGB [Cancer and Leukemia Group B]- 8811 and hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] regimens and the ALL-2 regimen) plus the addition of TKIs for Ph+ ALL and rituximab for CD20-positive ALL have resulted in 3-y survivals of 50% or more in adults. (medscape.com)
Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer. (nih.gov)
TECENTRIQ is currently approved by the FDA to treat people with locally advanced or mUC who have disease progression during or following platinum-based chemotherapy or whose disease has worsened within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy. (przoom.com)
TECENTRIQ is also approved for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. (przoom.com)
Cohort 1, upon which this sBLA submission is based, consisted of people who were ineligible for first-line cisplatin-based chemotherapy, and who had received no prior chemotherapies for locally advanced or mUC (i.e., first-line) or had disease progression at least 12 months after neoadjuvant or adjuvant chemotherapy. (przoom.com)
Cohort 2, which served as the basis for the FDA's accelerated approval of TECENTRIQ in May 2016, included people whose disease had progressed during or following previous treatment with a platinum-based chemotherapy regimen, or who had disease progression within 12 months of treatment with a platinum-based neoadjuvant or adjuvant chemotherapy regimen. (przoom.com)
In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)
In recent years, with a combination of autologous stem-cell transplantation and modern chemotherapy, the 10-y survival of patients presenting at an age less than 60 y is approximately 30% ( 1 , 2 ). (snmjournals.org)
as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
Patients with low-grade, low-stage disease may receive expectant treatment or may benefit from a single instillation of intravesical chemotherapy. (medscape.com)

The combination treatment of fecal microbiota transplantation with tislelizumab and fruquintinib was found to be manageably safe and resulted in improved survival in patients with microsatellite stable metastatic colorectal cancer. (news-medical.net)

Median (95% CI) relapse-free survival (RFS) censored and not censored at subsequent alloSCT were both 11.6 (2.7-20.5) and 11.7 months (2.8-20.5), respectively. (gilead.com)

Tumor shrinkage was seen in 80% of patients with stable disease. (biospace.com)
Background: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. (iiarjournals.org)
An independent, central radiology review board assessed disease progression and tumor shrinkage. (amgen.com)
Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)

Mutations in this particular gene are associated with a shorter duration of remission, decreased disease-free survival, and poor outcomes. (pharmacytimes.com)
The goals of therapy for AML include complete remission, restoration of normal hematopoietic functions, and no evidence of measurable residual disease. (pharmacytimes.com)

Previous studies have suggested that several factors are associated with recurrence or reduced survival, such as carcinoembryonic antigen, epithelial growth factor receptor, and cytokeratin-19 fragment ( 3 , 4 ). (iiarjournals.org)
13 Inclusion criteria comprised patients with a clear-cell component and met criteria for a high risk of recurrence (pT2 with nuclear grade 4 or sarcomatoid differentiation, pT3+, pTanyN+, or M1 NED post completely resected metastatic disease within 1 year of nephrectomy). (onclive.com)
Patients with T1-high grade or CIS are advised to undergo intravesical BCG immunotherapy because of the substantial risk of disease recurrence and progression. (medscape.com)

In the European Union, melphalan flufenamide is indicated, in combination with dexamethasone, for the treatment of adults with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. (wikipedia.org)

Our hope is that these results, along with our commitment to long-term research of Tecartus, will continue to provide clarity to physicians on optimal treatment methods for these patients living with this rare disease who have suffered historically poor outcomes. (gilead.com)
Of most importance, AML is a heterogenous disease and improved molecular understanding is increasing clinicians' abilities to predict outcomes and improve treatment. (pharmacytimes.com)
A total of 75% of participants with TB-related unfavorable outcomes had microbiological confirmation of failure to achieve a disease-free cure. (cdc.gov)

To determine if ado-trastuzumab emtansine (T-DM1) shows better progression-free survival (PFS) when compared to docetaxel plus trastuzumab (TH) in recurrent and/or metastatic (R/M) HER2-positive salivary gland cancer (SGC) patients who have not previously received HER2 therapy for unresectable or recurrent and/or metastatic disease, as determined by local assessment. (karmanos.org)
Patients with metastatic breast cancer assigned gemcitabine and vinorelbine had better progression-free survival compared with those assigned vinorelbine alone. (nih.gov)

Centers for Disease Control and Prevention. (cdc.gov)
The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. (cdc.gov)

In the United States, melphalan flufenamide is indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. (wikipedia.org)
ZUMA-3 is an ongoing international multicenter (US, Canada, Europe), single arm, open label, registrational Phase 1/2 study of Tecartus in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. (gilead.com)

The stable disease rate was 28 percent with panitumumab versus 10 percent with BSC alone. (amgen.com)
p = 0.01) than in those with stable disease. (ersjournals.com)

5. Patients with a previous history of demyelinating or inflammatory diseases of the Central Nervous System (CNS) or Peripheral (SNP). (who.int)

Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
Mesothelioma can be a devastating diagnosis for patients and their families, and the disease has a significant impact throughout Europe, which has the highest incidence rate of mesothelioma globally," said Stefania Vallone, board member, Women Against Lung Cancer in Europe. (pharmiweb.com)
The trial found that people taking abemaciclib had a higher invasive disease-free survival rate , meaning they were less likely to have breast cancer come back in the time studied. (lbbc.org)
The 3-year rate of invasive disease-free survival was 90.4% with ribociclib vs 87.1% with hormonal therapy alone. (ascopost.com)
The CIS group, which had a median follow-up of 23.9 months, had a 71% CR rate with a median 26.6-month duration of CR, Dr Chamie reported. (renalandurologynews.com)

Such mild effects are particularly important for follicular lymphoma patients, who are diagnosed with the disease at a median age of 60. (sciencedaily.com)

Both study treatments were administered intravenously every 21 days until disease progression, unacceptable toxic effects, or stoppage at the request of investigator or patient. (nih.gov)

We were attempting to improve tolerability while maintaining efficacy, based on the observation that efficacy was maintained in patients with metastatic disease on lower doses of CDK4/6 inhibitors. (ascopost.com)
At the second efficacy analysis, there was a 25% relative reduction in the risk of invasive breast cancer, and the benefit was seen across all subgroups, regardless of disease stage, menopausal status, or nodal status. (ascopost.com)

Median progression-free survival for all patients was 18.8 months but had not been reached for the 19 responders. (sciencedaily.com)
Results: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). (iiarjournals.org)
For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
The median duration of follow-up was 35 months. (nih.gov)
Median progression-free survival was 5.9 months (95% CI = 2.8 months to not reached). (ascopost.com)
Median progression-free survival was 6.8 months among 15 patients with non-T790M mutations or whose T790M status was unknown, compared with 3.7 months among 13 patients with a T790M mutation. (ascopost.com)
ESMO 2022 Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability. (medscape.com)
Patients with metastatic disease were randomly assigned to receive 12 cycles of FOLFIRINOX (arm A), 8 cycles of FOLFIRINOX followed by maintenance therapy with fluorouracil + leucovorin (arm B), or a sequential treatment alternating gemcitabine and fluorouracil/leucovorin/irinotecan every 2 months (arm C). According to Dr. Tempero, the median durations of OS did not seem to differ between arms A and B (10.1 vs 11.2 months). (jnccn.org)
The median duration of follow-up for invasive disease-free survival was 27.7 months for both arms of the study. (ascopost.com)
In a phase 1b trial, administration of intravesical N-803 plus BCG in BCG-naïve patients with NMIBC induced CR without recurrences for the study duration of 24 months, according to investigators. (renalandurologynews.com)
Bladder cancer-specific survival was 100% at 24 months. (renalandurologynews.com)
Deep responses with uMRD were associated with superior progression-free survival (PFS) of VenR vs BR with 48 months (mo) follow-up (f/u). (confex.com)
Patients diagnosed with this disease have a poor prognosis, with survival rates of 14 to 15 months after diagnosis. (jnccn.org)
Conventional wisdom has been that new incident obstructive airway disease (OAD) that is associated with environmental or occupational exposure would present weeks to months, not years, after exposure. (cdc.gov)
Eligible studies compared 3HP or 4R to 6 months or 9 months of isoniazid and reported treatment completion, adverse events, or incidence of tuberculosis disease. (cdc.gov)

Results showed that disease-free survival (DFS) was significantly longer in patients who received pembrolizumab, with 24-month DFS rates at 77.3% with pembrolizumab vs 68.1% with placebo (HR, 0.68, P = .002). (onclive.com)

NCT03022825 ), which included 161 patients with BCG-unresponsive high-risk NMIBC divided into 2 cohorts: 84 patients with carcinoma in situ (CIS) and 77 with papillary disease. (renalandurologynews.com)
and each of those cohorts was 30 patients in different disease types. (urotoday.com)

The relative risks of progression of disease or death were 0.57 (95 percent confidence interval, 0.42 to 0.78) in group 1 and 0.55 (95 percent confidence interval, 0.40 to 0.75) in group 2, as compared with group 3. (nih.gov)

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. (businesswire.com)
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. (businesswire.com)
A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment. (nepalnews.com)
Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
'Unprecedented' 3-Year Sustained Survival in SCLC With New Combo The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). (medscape.com)
A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. (przoom.com)
With the European Commission approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease. (pharmiweb.com)
On May 23, ImmunityBio Inc, which is developing N-803, announced that it submitted a Biologics License Application to the US Food and Drug Administration for N-803 for use with BCG as a treatment for BCG-unresponsive NMIBC CIS with or without Ta or T1 disease. (renalandurologynews.com)
In collaboration with the National Cancer Institute, two groups of patients with Stage III colon cancer (one of them being a placebo or control group) were randomly assigned to various community and academic centers throughout the U.S. and Canada to be evaluated during the duration of their treatment. (coloncancerfoundation.org)
Cox regression analysis revealed that factors associated with transplant free survival were: AZA use before transplantation (p = 0.012, OR 2.3, 95% CI 1.2-4.4), treatment with steroids pre-LT (p = 0.001, OR 4.7, 95% CI 2.2-10.1) and concomitant IBD (p = 0.023. (bmj.com)
Limited treatment options currently exist after disease progression on standard-of-care first-line therapy. (jnccn.org)
They cite recommendations from European and United States guidelines, as well as published literature showing a 75% 5-year cancer-specific survival for all stages of bladder cancer treated with cystectomy, while noting that the published literature on trimodality therapy shows evidence of inferior survival and frequent treatment failure, with almost one-third of patients eventually requiring a salvage cystectomy. (medscape.com)
Treatment protocols for gastrointestinal stromal tumors (GISTs) are provided below, including those for limited-stage disease and persistent or metastatic disease. (medscape.com)
once initiated, duration of treatment is unknown and will likely need to continue for several years, if not for life. (cdc.gov)

The diagnosis of Alzheimer's disease can be made with considerable accuracy in this stage. (alzinfo.org)
Five-year survival is dependent on stage at diagnosis: 93% for stage I, 72.5% for stage II/III, and 12% for stage IV metastatic disease. (onclive.com)
Extramedullary disease is typically an aggressive, poorly differentiated form of MM that confers inferior outcome, with median survival of less than 1 y if present at diagnosis. (snmjournals.org)
A laboratory diagnosis-based epidemiologic surveillance system can provide substantial information about disease transmission and effective prevention strategies. (cdc.gov)

Individuals with another concomitant cancer, autoimmune disease, a history of immunotherapy or organ transplantation, any factors that would impact the absorption of oral drugs, and those prescribed systemic immunosuppressive therapy were excluded from the study. (news-medical.net)
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease, and COVID-19. (itbusinessnet.com)

[ 80 ] For example, presence of the MRE11A single-nucleotide polymorphism rs1805363 has been associated with worse cancer-specific survival after radiation therapy, with a gene-dosage effect observed, but not after cystectomy. (medscape.com)

If real disease progression can be defined in terms of marginal PFT thresholds, then their inclusion in clinical decision-making and in therapeutic trial end-points would allow increased recognition of clinically relevant disease behaviour. (ersjournals.com)

however, the strength of the recommendation to treat should be based on the patient's willingness to accept therapy as well as the prognosis for AIDS-free survival as determined by the HIV RNA copy per mL of plasma and the CD4+ T cell count. (cdc.gov)

Researchers from UCLA Jonsson Comprehensive Cancer Centre found that individuals who received the combination therapy had much longer invasive disease-free life than those who received hormone therapy alone, regardless of whether the cancer had progressed to the lymph nodes. (nepalnews.com)
At the time of this analysis, 189 people in the ribociclib group experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group. (nepalnews.com)
The SAFRON II trial "provides strong data that support ablative therapy in patients with oligometastatic lung disease, demonstrating high rates of local control, minimal toxic effects, and the potential for the lung organ system to stimulate immune activation," wrote Arya Amini, MD, of City of Hope National Medical Center in Duarte, California, in an accompanying commentary . (medpagetoday.com)
The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy significantly improved invasive disease-free survival in women with hormone receptor-positive, HER2-negative, early-stage breast cancer. (ascopost.com)
All patients who have advanced or symptomatic HIV disease should receive aggressive antiretroviral therapy. (cdc.gov)

Persons with these symptoms decline at higher rates than similarly aged persons and similarly healthy persons who are free of subjective complaints. (alzinfo.org)

Introduction Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease, progressive in the majority of cases. (bmj.com)
Conclusion In our big cohort of patients affected by primary sclerosing cholangitis, use of AZA and steroids before LT significantly prolonged transplant free survival. (bmj.com)

However, considering that single-fraction SABR is of shorter duration than multifraction SABR, it may be more preferable for patients and is a good candidate for investigation in future trials, the authors pointed out. (medpagetoday.com)

The indiscriminate use of gefitinib or erlotinib in the general lung cancer population results in meager survival benefit for patients. (aacrjournals.org)

Patients with concomitant IBD had an increased transplant free survival compared to those without IBD. (bmj.com)

Bacillus Calmette-Guérin (BCG) immunotherapy or other intravesical chemotherapies may be used for patients with recurrent disease or those at intermediate risk, although they are not necessary for all high-risk patients. (medscape.com)

Interstitial Lung Disease (ILD): Permanently discontinue VIZIMPRO if ILD is confirmed. (nih.gov)
02:53 Comorbidity is like lung disease. (yalecancercenter.org)
Inhaled uranium particulate can produce lung disease. (cdc.gov)

While other phase II randomized trials of patients with oligometastatic disease have demonstrated an advantage in DFS and OS with SABR over standard systemic therapies alone, "no high-level evidence or consensus is available on the optimal dose and fractionation schedule for SABR in oligometastatic disease," Siva and colleagues noted. (medpagetoday.com)
Second, the study used a 400-mg dose of ribociclib, which is lower than that approved in metastatic disease (600 mg/d for 3 weeks with 1 week off per cycle). (ascopost.com)
The bacteriostatic water for injection is a colourless, transparent solution, free of visible particles and is intended to use for the reconstitution of [BT-ON014 trade name] to yield a multi-dose solution containing 21 mg/mL trastuzumab at a pH of approximately 6.0. (who.int)

246 (67%) were diagnosed with IBD: 208 ulcerative colitis, 30 Crohn's disease, 8 indeterminate colitis. (bmj.com)

Anatomy10

Organisms9

Diseases58

Chemicals and Drugs52

Analytical, Diagnostic and Therapeutic Techniques and Equipment86

Psychiatry and Psychology1

Phenomena and Processes34

Disciplines and Occupations1

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science9

Named Groups2

Health Care40

Geographicals2

Progression or unacceptable toxicity4

Endpoint6

Invasive disease-free survival rates2

Response28

Chemotherapy11

Colorectal Cancer1

Relapse-free survival1

Tumor4

Remission2

Recurrence3

Demonstrated disease progression1

Outcomes3

Better progression-free sur2

Centers for Diseas2

Whose disease is refractory2

Stable disease2

Inflammatory1

Rate5

Median age1

Unacceptable1

Efficacy2

Months15

Patients who received pembrolizumab1

Cohorts2

Confidence interval1

Treatment14

Diagnosis4

Autoimmune disease2

Cancer-specific survival1

Clinically1

Prognosis1

Therapy5

Rates1

Primary2

Shorter duration1

Benefit1

Concomitant1

Recurrent1

Lung disease3

Dose3

Crohn's1